Table 1 Questionnaire on the treatment of COVID-19 in patients receiving dialysis therapy

Select the severity of the admitted patients (mild, moderate disease I; moderate disease II; severe).

Describe the number of dialysis patients (including peritoneal dialysis and combination therapy) with COVID-19.

(1) Were antivirals administered to patients with mild disease?

Describe the type of antivirals administered.

(2) Were antivirals were administered to patients with moderate I or more severe disease?

Describe the type of antivirals administered.

Describe the protocol of remdesivir if administered.

(3) When were steroids initiated? Select the severity of the disease (mild, moderate disease I; moderate disease II; severe).

(4) Describe the type, dose, method, and duration of steroids (the standard therapy consists of dexamethasone 6 mg for 10 days).

(5) Was steroid pulse therapy ever applied?

Describe the treatment protocols and their criteria.

(6) Was the duration of steroid administration prolonged?

What parameters were used when extending the duration of treatment?

(7) Was tocilizumab or baricitinib ever applied?

Describe the criteria.

(8) Were the membranes and anticoagulants changed during dialysis?

Specify the details.

(9) Was continuous hemodiafiltration (CHDF) or polymyxin B-immobilized fiber column-direct hemoperfusion used in severe cases?

Describe the criteria for starting CHDF, membranes, and anticoagulants.

Describe the criteria for using PMX-DHP.

(10) Have you ever applied extracorporeal membrane oxygenation?

Describe the criteria and its prognosis if you have.

Describe the reasons if you have not.

(11) Are the discharge criteria for patients undergoing dialysis the same as those for general patients?

Describe the discharge criteria.

(12) Do you explain `Do Not Attempt Resuscitation' on admission?